GlobeNewsWire
12 Aug 2026, 10:50 UTC · 59m ago
Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
GlobeNewsWire
12 Aug 2026, 10:50 UTC · 59m ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Pharvaris expects to announce pivotal data from the CHAPTER-3 study within the current quarter. — Pivotal clinical trial data is the primary value driver for late-stage biotech firms and typically triggers significant price volatility.
+0.80Financing completed in May 2026 has extended the company's cash runway into 2028. — Securing funding through 2028 reduces immediate dilution risk and provides stability for the upcoming product launch.
+0.50The company is conducting pre-commercial activities to support a timely U.S. launch of deucrictibant IR. — Transitioning from development to commercialization increases the probability of near-term revenue generation.
+0.40Which stocks this story touches
Continue reading
6 related stories
Top 3 movers · tap to explore
The company reports strong progress toward regulatory approval for deucrictibant and has extended its cash runway into 2028.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
59m ago
